JP2016523961A5 - - Google Patents

Info

Publication number

JP2016523961A5

JP2016523961A5 JP2016525357A JP2016525357A JP2016523961A5 JP 2016523961 A5 JP2016523961 A5 JP 2016523961A5 JP 2016525357 A JP2016525357 A JP 2016525357A JP 2016525357 A JP2016525357 A JP 2016525357A JP 2016523961 A5 JP2016523961 A5 JP 2016523961A5

Authority

JP

Japan

Prior art keywords

tumors

use according

medicament

mucin

glycan

Prior art date

2014-06-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims 14
• 108090000288 Glycoproteins Proteins 0.000 claims 6
• 102000003886 Glycoproteins Human genes 0.000 claims 6
• 230000037361 pathway Effects 0.000 claims 5
• 206010028980 Neoplasm Diseases 0.000 claims 4
• 201000011510 cancer Diseases 0.000 claims 4
• 230000005754 cellular signaling Effects 0.000 claims 4
• 229940127089 cytotoxic agent Drugs 0.000 claims 4
• 239000002254 cytotoxic agent Substances 0.000 claims 4
• 231100000599 cytotoxic agent Toxicity 0.000 claims 4
• 239000012634 fragment Substances 0.000 claims 4
• 230000001686 pro-survival effect Effects 0.000 claims 4
• 239000003795 chemical substances by application Substances 0.000 claims 3
• 230000005764 inhibitory process Effects 0.000 claims 3
• 230000004614 tumor growth Effects 0.000 claims 3
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 2
• 208000026310 Breast neoplasm Diseases 0.000 claims 2
• 206010019695 Hepatic neoplasm Diseases 0.000 claims 2
• KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 claims 2
• RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 claims 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
• 229940028652 abraxane Drugs 0.000 claims 2
• 230000004913 activation Effects 0.000 claims 2
• 239000000427 antigen Substances 0.000 claims 2
• 102000036639 antigens Human genes 0.000 claims 2
• 108091007433 antigens Proteins 0.000 claims 2
• 230000000973 chemotherapeutic effect Effects 0.000 claims 2
• 238000009104 chemotherapy regimen Methods 0.000 claims 2
• 208000029742 colonic neoplasm Diseases 0.000 claims 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
• 229960005277 gemcitabine Drugs 0.000 claims 2
• 230000002401 inhibitory effect Effects 0.000 claims 2
• 208000014018 liver neoplasm Diseases 0.000 claims 2
• 208000037841 lung tumor Diseases 0.000 claims 2
• 201000002528 pancreatic cancer Diseases 0.000 claims 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
• 229940124597 therapeutic agent Drugs 0.000 claims 2
• 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
• 230000007730 Akt signaling Effects 0.000 claims 1
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
• 102100023123 Mucin-16 Human genes 0.000 claims 1
• 108091007960 PI3Ks Proteins 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 229950007283 oregovomab Drugs 0.000 claims 1
• 230000008685 targeting Effects 0.000 claims 1